Chief Operating Officer (10) · Adaptive Biotechnologies Corp (ADPT)

Mark Adams

FY2020 is the first fiscal year CompBrief holds for Mark Adams as a named executive officer of Adaptive Biotechnologies; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$2,699,999

Salary $280,859Stock awards $1,405,000

4th of 5 named executive officers at Adaptive Biotechnologies by FY2020 total.

5 named officers on file for Adaptive Biotechnologies, FY2020

Mark Adams’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • ADPT’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Adaptive Biotechnologies’s whole pay program stands against its peers

  • Adaptive Biotechnologies’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2021 (DEF 14A).

Free

Get Mark Adams’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Adams compensation by year

Adaptive Biotechnologies Summary Compensation Table · the one fiscal year held
In US dollars, as Adaptive Biotechnologies reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$280,859
Bonus$0
Stock awards$1,405,000
Option awards$891,595
Non-equity incentive$112,022
Pension and deferred compensation$0
All other$10,523
Total$2,699,999

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptive Biotechnologies Corp DEF 14A filed April 23, 2021, accession 0001564590-21-020371, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Adaptive Biotechnologies Corp filed document, accession 0001564590-21-020371. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU50,000$2,956,500—
Option50,000—$28.10

Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptive Biotechnologies Corp's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Adaptive Biotechnologies’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Chad RobinsChief Scientific Officer$7,131,118
Harlan RobinsChief Scientific Officer$6,761,270
Julie RubinsteinPresident$4,743,855
Mark Adams · this pageChief Operating Officer (10)$2,699,999
Chad CohenFormer Chief Financial Officer$2,329,752

The full Adaptive Biotechnologies compensation record

free company brief

This page is one person within Adaptive Biotechnologies's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Adaptive Biotechnologies proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptive Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Adams's compensation dossier · One-time report. No refunds.